Mirum Pharmaceuticals

MIRMApproved

Mirum Pharmaceuticals is dedicated to addressing severe unmet needs in rare liver diseases through its expertise in ileal bile acid transporter (IBAT) inhibition. The company has successfully commercialized LIVMARLI® and is advancing a robust clinical pipeline, including brelovitug for chronic hepatitis delta virus. With a patient-centric approach and a seasoned leadership team, Mirum aims to deliver life-changing medicines to underserved patient communities globally.

Market Cap

$5.3B

Focus

Small Molecules

MIRM · Stock Price

USD 88.51+65.80 (+289.74%)

Historical price data

AI Company Overview

Technology Platform

Mirum's core platform is based on selective ileal bile acid transporter (IBAT) inhibition, which aims to reduce toxic bile acid accumulation in the liver by increasing their fecal excretion, thereby addressing the root cause and symptoms of various cholestatic and metabolic liver diseases.

Pipeline Snapshot

37 drugs in pipeline, 12 in Phase 3

Drug	Indication	Stage
Livmarli Oral Product	Alagille Syndrome	Approved
Maralixibat	Progressive Familial Intrahepatic Cholestasis (PFIC)	Phase 3
Maralixibat	Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)	Phase 3
Cholic acid	Inborn Errors of Bile Acid Synthesis	Phase 3
Brelovitug 300 mg + Bulevirtide 2 mg and Brelovitug - 300 mg	Chronic Hepatitis D Infection	Phase 3

Funding History

Total raised: $420M

PIPE$175MRA Capital ManagementJun 15, 2021

IPO$125MUndisclosedJul 18, 2019

Series A$120MFrazier Healthcare PartnersJun 15, 2018

FDA Approved Drugs

LIVMARLINDAApr 10, 2025

CTEXLINDAFeb 21, 2025

LIVMARLINDASep 29, 2021

Opportunities

Significant growth opportunities exist from expanding LIVMARLI® into larger cholestatic disease populations (PSC, PBC) and from successfully launching brelovitug in the substantial chronic hepatitis delta virus market.

Geographic expansion of existing products also presents a clear near-term opportunity.

Risk Factors

Key risks include clinical trial failures in late-stage pipeline programs (EXPAND, AZURE), slower-than-expected commercial adoption of LIVMARLI®, increasing competition in the HDV space, and the potential need to raise additional capital before achieving profitability.

Competitive Landscape

In cholestasis, LIVMARLI® competes against off-label therapies and other IBAT inhibitors. In hepatitis delta, brelovitug will face competition from approved injectable therapy (bulevirtide in EU) and other late-stage oral candidates. Mirum differentiates through its first-mover advantage in cholestatic pruritus, oral dosing, and deep hepatology expertise.

Publications

Patents

Pipeline

FDA Approvals